| Objective:To evaluate the efficacy and safety of intravitreal injection of conbercept in the treatment of choroidal neovascularization(CNV)secondary to high myopia and to observe the application of optical coherence tomography angiography(OCTA)in the treatment follow-up.Methods:The study was a retrospective analytical case series.We reviewed medical records of 20 patients 21 eyes with choroidal neovascularization secondary to high myopia that enrolled in Department of Ophthalmology of the First Hospital of China Medical University from May 2018 to May 2019.Each patient received one or more intravitreal injections of conbercept(0.5 mg/0.05 mL).The treatment was conducted with1+PRN(pro re nata)regimen.Patients were observed at baseline and 1 month,2 months,3 months,and 6 months'follow-up after treatment.At each visit,best corrected visual acuity(BCVA),central macular thickness,intraocular pressure,and selected CNV area and flow area measured by OCTA were observed over a 6-month follow-up period.Results:Totally 20 patients(21 eyes)were enrolled in this study.There were 18 eyes from 18 women and 3 eyes from 2 men.The mean age was 58.95±12.28 years.Total of49 intravitreal injections were given during the 6-month's treatment,with a mean of 2.33injections per eye.Nineteen of the 21 eyes(90.48%)needed reinjections(rang 2-4injections),of which 12,5 and 2 eyes required 2,3 and 4 injections,respectively.The mean logarithm of the minimum angle of resolution(LogMAR)BCVA was 1.03±0.61before treatment and improved to 0.83±0.59(t=2.980,P=0.007),0.78±0.62(t=3.735,P=0.001),0.81±0.73(t=2.394,P=0.027),0.79±0.72(t=2.469,P=0.023)at 1 month,2 months,3 months,and 6 months after treatment,respectively.The differences were statistically significant compared with baseline(P<0.05),while,there were no statistically significant differences between the groups(P>0.05).The mean CMT was 358.16±206.11?m before treatment,and it was respectively 295.38±178.70?m(t=3.435,P=0.003),288.34±165.60?m(t=3.260,P=0.004),284.36±163.07?m(t=3.138,P=0.005),283.00±160.32?m(t=3.242,P=0.004)after 1 mo,2 mo,3 mo and6 mo of treatment.The differences were statistically significant compared with baseline(P<0.05).But there were no statistically significant differences between the groups(P>0.05).Before treatment,the mean intraocular pressure was 16.67±2.39 mmHg,and the mean intraocular pressure was respectively 16.77±1.98 mmHg,16.43±2.31 mmHg,16.33±2.24 mmHg,16.24±1.81 mmHg after 1 mo,2 mo,3 mo and 6 mo of treatment.The differences were not statistically significant(P>0.05).The mean selected CNV area and blood flow area before treatment were 0.62±0.81 mm~2,0.22±0.27 mm~2,while after1 month the average areas were 0.23±0.33 mm~2,0.07±0.08mm~2,respectively.The differences were statistically significant compared with baseline(P=0.04 for Both).And there was no case of endophthalmitis,retinal detachment and stroke during follow-up.Conclusion:Conbercept can effectively and safely improve the best-corrected vision and reduce the central macular thickness in patients with mCNV.No significant adverse events are observed.At the same time,OCTA can be used to observe the CNV area,the blood flow area and CNV morphological changes after treatment with Conbercept,which provides a reference for clinical diagnosis and treatment follow-up. |
PDF Full Text Request